|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2001-10-10
|
|
pubmed:abstractText |
Therapies that deplete lymphocytes often improve symptoms in patients with otherwise refractory autoimmune disease but may result in long-term lymphopenia, the consequences of which are uncertain. To assess the impact of prolonged lymphopenia on morbidity and mortality, we studied patients who had previously received lymphocytotoxic monoclonal antibody (mAb) therapy for rheumatoid arthritis (RA).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1998-2008
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11592360-Aged,
pubmed-meshheading:11592360-Antibodies, Monoclonal,
pubmed-meshheading:11592360-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:11592360-Antibodies, Neoplasm,
pubmed-meshheading:11592360-Antirheumatic Agents,
pubmed-meshheading:11592360-Arthritis, Rheumatoid,
pubmed-meshheading:11592360-Cohort Studies,
pubmed-meshheading:11592360-Follow-Up Studies,
pubmed-meshheading:11592360-Humans,
pubmed-meshheading:11592360-Immunotherapy,
pubmed-meshheading:11592360-Lymphocyte Subsets,
pubmed-meshheading:11592360-Lymphopenia,
pubmed-meshheading:11592360-Middle Aged,
pubmed-meshheading:11592360-Prognosis,
pubmed-meshheading:11592360-Retrospective Studies,
pubmed-meshheading:11592360-Survival Analysis
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
|
|
pubmed:affiliation |
University of Leeds, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
